Share Price and Basic Stock Data
Last Updated: January 29, 2026, 6:25 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
JHS Svendgaard Laboratories Ltd operates within the personal care industry, focusing on manufacturing oral care products. The company reported a current share price of ₹10.4, with a market capitalization of ₹88.4 Cr. The revenue performance has shown fluctuations, with sales of ₹21.05 Cr in September 2022, peaking at ₹25.17 Cr in March 2025, and recording a trailing twelve-month (TTM) revenue of ₹93.56 Cr. However, the revenue dipped to ₹70.80 Cr in March 2024. The sales trajectory indicates variability, particularly with a significant decline to ₹15.90 Cr in June 2023. This suggests challenges in maintaining consistent growth, possibly influenced by market competition and operational issues. The company’s operations faced considerable expenses, which stood at ₹25.28 Cr in March 2023, contributing to a net profit loss of ₹17.52 Cr for the same period. Overall, while the company has shown the ability to generate revenue, the inconsistency raises concerns about its long-term growth potential.
Profitability and Efficiency Metrics
Profitability metrics for JHS Svendgaard Laboratories Ltd reveal significant challenges. The operating profit margin (OPM) stood at -10.69% in March 2023, reflecting ongoing operational difficulties. The company has struggled to achieve positive operating profit, with a recorded operating loss of ₹9.07 Cr in the same fiscal year. The interest coverage ratio (ICR) was reported at -2.01x, indicating that the company’s earnings are insufficient to cover its interest obligations. Furthermore, net profit margins have consistently remained negative, with a net profit margin of -21.46% in March 2025. Efficiency ratios also tell a concerning story; the cash conversion cycle (CCC) was 63 days, while inventory days extended to 153 days, indicating potential inefficiencies in inventory management. These metrics highlight the need for operational improvements to enhance profitability and overall financial health.
Balance Sheet Strength and Financial Ratios
JHS Svendgaard Laboratories Ltd’s balance sheet reflects a mixed picture of financial health. As of September 2025, the company reported total assets of ₹206.90 Cr, with total liabilities of ₹206.90 Cr, indicating a balanced but potentially risky financial structure. Borrowings stood at ₹10.59 Cr, which is relatively low compared to the overall market capitalization. The company’s return on equity (ROE) was reported at 10.8%, which is respectable, but low compared to typical sector benchmarks. The price-to-book value (P/BV) ratio was low at 0.55x, suggesting that the stock may be undervalued compared to its net assets. However, the company faced a negative interest coverage ratio, emphasizing concerns over its ability to meet debt obligations. The financial ratios indicate a need for caution, as the company navigates a challenging operating environment while attempting to stabilize its financial position.
Shareholding Pattern and Investor Confidence
The shareholding pattern of JHS Svendgaard Laboratories Ltd illustrates a diverse ownership structure, with promoters holding 34.56% of the equity as of September 2025. The public holds a significant stake of 63.87%, indicating a broad base of retail investor interest. However, institutional participation remains low, with foreign institutional investors (FIIs) at 1.57% and domestic institutional investors (DIIs) at 0.00%. This limited institutional backing may reflect concerns about the company’s financial performance and operational challenges. The number of shareholders stood at 25,007, showing a slight decline compared to earlier periods, which could indicate waning investor confidence. The fluctuating promoter shareholding, which declined from 42.23% in December 2022 to the current 34.56%, may also contribute to uncertainties regarding corporate governance and future strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, JHS Svendgaard Laboratories Ltd faces a challenging landscape with both risks and potential opportunities. Key strengths include its established presence in the personal care sector and a diverse product range, which could be leveraged for growth. However, significant risks stem from its inconsistent revenue trends, negative profitability margins, and low operational efficiency. The company’s ability to improve its operational metrics and manage its financial structure will be critical in navigating these challenges. Moreover, the reliance on a high public shareholding without substantial institutional backing raises concerns about long-term strategic support. If the company can stabilize its operations and regain investor confidence, it may unlock growth potential. Conversely, failure to address operational inefficiencies and maintain financial health could hinder its recovery and growth prospects.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Honasa Consumer Ltd | 8,709 Cr. | 268 | 334/190 | 70.0 | 38.8 | 0.00 % | 7.44 % | 5.51 % | 10.0 |
| Ambica Agarbathies Aroma & Industries Ltd | 40.9 Cr. | 24.0 | 37.0/22.3 | 80.1 | 65.2 | 0.00 % | 7.49 % | 0.45 % | 10.0 |
| Ador Multi Products Ltd | 121 Cr. | 126 | 149/23.4 | 32.5 | 0.00 % | 11.4 % | 3.09 % | 10.0 | |
| Kaya Ltd | 501 Cr. | 331 | 488/204 | 60.9 | 0.00 % | 2.50 % | % | 10.0 | |
| Jyothy Labs Ltd | 8,999 Cr. | 245 | 423/243 | 24.6 | 55.8 | 1.43 % | 24.6 % | 19.0 % | 1.00 |
| Industry Average | 69,431.43 Cr | 1,835.19 | 56.21 | 112.70 | 0.81% | 29.21% | 23.91% | 4.94 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.05 | 22.19 | 21.72 | 15.90 | 18.93 | 14.30 | 21.66 | 24.48 | 19.68 | 22.66 | 25.17 | 23.45 | 22.28 |
| Expenses | 23.02 | 24.41 | 25.28 | 18.02 | 18.52 | 14.36 | 20.82 | 22.51 | 20.52 | 22.41 | 30.55 | 21.79 | 21.37 |
| Operating Profit | -1.97 | -2.22 | -3.56 | -2.12 | 0.41 | -0.06 | 0.84 | 1.97 | -0.84 | 0.25 | -5.38 | 1.66 | 0.91 |
| OPM % | -9.36% | -10.00% | -16.39% | -13.33% | 2.17% | -0.42% | 3.88% | 8.05% | -4.27% | 1.10% | -21.37% | 7.08% | 4.08% |
| Other Income | 2.52 | 0.94 | -11.54 | 0.41 | 0.20 | 2.34 | 1.37 | 0.32 | 0.86 | 0.27 | -1.44 | 1.00 | 1.14 |
| Interest | 0.12 | 0.16 | 0.11 | 0.13 | 0.10 | 0.11 | 0.13 | 0.12 | 0.11 | 0.13 | 0.21 | 0.16 | 0.20 |
| Depreciation | 1.49 | 1.46 | 1.61 | 1.32 | 1.50 | 1.63 | 1.90 | 1.97 | 1.98 | 1.97 | 2.02 | 1.88 | 1.86 |
| Profit before tax | -1.06 | -2.90 | -16.82 | -3.16 | -0.99 | 0.54 | 0.18 | 0.20 | -2.07 | -1.58 | -9.05 | 0.62 | -0.01 |
| Tax % | -13.21% | -4.83% | -36.39% | -18.35% | -26.26% | 100.00% | 516.67% | 415.00% | 398.07% | 15.82% | -23.09% | -69.35% | 1,800.00% |
| Net Profit | -0.92 | -2.76 | -10.71 | -2.59 | -0.73 | 0.01 | -0.75 | -0.63 | -10.32 | -1.84 | -6.96 | 1.06 | -0.20 |
| EPS in Rs | -0.14 | -0.43 | -1.65 | -0.40 | -0.09 | 0.00 | -0.10 | -0.08 | -1.21 | -0.21 | -0.81 | 0.12 | -0.02 |
Last Updated: December 30, 2025, 9:16 am
Below is a detailed analysis of the quarterly data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 22.28 Cr.. The value appears to be declining and may need further review. It has decreased from 23.45 Cr. (Jun 2025) to 22.28 Cr., marking a decrease of 1.17 Cr..
- For Expenses, as of Sep 2025, the value is 21.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 21.79 Cr. (Jun 2025) to 21.37 Cr., marking a decrease of 0.42 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.91 Cr.. The value appears to be declining and may need further review. It has decreased from 1.66 Cr. (Jun 2025) to 0.91 Cr., marking a decrease of 0.75 Cr..
- For OPM %, as of Sep 2025, the value is 4.08%. The value appears to be declining and may need further review. It has decreased from 7.08% (Jun 2025) to 4.08%, marking a decrease of 3.00%.
- For Other Income, as of Sep 2025, the value is 1.14 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 1.14 Cr., marking an increase of 0.14 Cr..
- For Interest, as of Sep 2025, the value is 0.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.16 Cr. (Jun 2025) to 0.20 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Sep 2025, the value is 1.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.88 Cr. (Jun 2025) to 1.86 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Jun 2025) to -0.01 Cr., marking a decrease of 0.63 Cr..
- For Tax %, as of Sep 2025, the value is 1,800.00%. The value appears to be increasing, which may not be favorable. It has increased from -69.35% (Jun 2025) to 1,800.00%, marking an increase of 1,869.35%.
- For Net Profit, as of Sep 2025, the value is -0.20 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Jun 2025) to -0.20 Cr., marking a decrease of 1.26 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.02. The value appears to be declining and may need further review. It has decreased from 0.12 (Jun 2025) to -0.02, marking a decrease of 0.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.28 | 55.10 | 99.62 | 104.18 | 140.29 | 123.99 | 139.11 | 100.77 | 86.25 | 84.81 | 70.80 | 92.00 | 93.56 |
| Expenses | 39.06 | 58.95 | 93.11 | 92.45 | 126.34 | 123.89 | 137.40 | 98.80 | 87.09 | 93.88 | 71.73 | 96.01 | 96.12 |
| Operating Profit | -3.78 | -3.85 | 6.51 | 11.73 | 13.95 | 0.10 | 1.71 | 1.97 | -0.84 | -9.07 | -0.93 | -4.01 | -2.56 |
| OPM % | -10.71% | -6.99% | 6.53% | 11.26% | 9.94% | 0.08% | 1.23% | 1.95% | -0.97% | -10.69% | -1.31% | -4.36% | -2.74% |
| Other Income | -2.67 | -5.79 | -17.30 | 0.39 | 32.03 | 5.97 | 3.16 | 7.49 | 9.39 | -7.31 | 4.31 | 0.02 | 0.97 |
| Interest | 14.14 | 0.14 | 0.36 | 0.62 | 0.74 | 1.03 | 1.95 | 1.24 | 1.39 | 0.55 | 0.46 | 0.57 | 0.70 |
| Depreciation | 14.71 | 12.36 | 10.49 | 6.36 | 6.81 | 7.09 | 8.76 | 7.25 | 7.05 | 6.02 | 6.35 | 7.95 | 7.73 |
| Profit before tax | -35.30 | -22.14 | -21.64 | 5.14 | 38.43 | -2.05 | -5.84 | 0.97 | 0.11 | -22.95 | -3.43 | -12.51 | -10.02 |
| Tax % | -18.39% | 0.18% | 0.00% | -326.85% | 32.19% | -18.54% | -16.95% | -39.18% | 4,000.00% | -23.66% | 18.37% | 57.87% | |
| Net Profit | -28.81 | -22.18 | -21.64 | 21.94 | 26.06 | -1.67 | -4.86 | 1.34 | -4.29 | -17.52 | -4.06 | -19.74 | -7.94 |
| EPS in Rs | -11.95 | -9.20 | -5.76 | 4.98 | 4.29 | -0.11 | -0.33 | 0.19 | -0.62 | 0.62 | -0.52 | -2.31 | -0.92 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 23.01% | 2.43% | 201.39% | 18.78% | -106.41% | -191.02% | 127.57% | -420.15% | -308.39% | 76.83% | -386.21% |
| Change in YoY Net Profit Growth (%) | 0.00% | -20.58% | 198.95% | -182.61% | -125.19% | -84.61% | 318.59% | -547.72% | 111.76% | 385.22% | -463.03% |
JHS Svendgaard Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -8% |
| 3 Years: | 2% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -624% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -9% |
| 3 Years: | -23% |
| 1 Year: | -61% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 8:15 am
Balance Sheet
Last Updated: December 10, 2025, 2:54 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24.10 | 24.10 | 37.64 | 44.12 | 60.90 | 60.90 | 60.90 | 64.40 | 64.90 | 78.40 | 78.40 | 85.60 | 85.60 |
| Reserves | 38.01 | 95.50 | 62.95 | 90.25 | 113.36 | 115.94 | 117.10 | 124.30 | 121.00 | 95.44 | 91.49 | 87.12 | 88.04 |
| Borrowings | 54.12 | 18.82 | 2.56 | 2.31 | 2.49 | 7.19 | 8.58 | 7.01 | 6.19 | 2.58 | 5.13 | 6.46 | 10.59 |
| Other Liabilities | 74.19 | 32.93 | 19.26 | 18.57 | 31.59 | 38.54 | 54.88 | 32.72 | 30.01 | 51.81 | 22.04 | 24.62 | 22.67 |
| Total Liabilities | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
| Fixed Assets | 120.88 | 107.89 | 65.10 | 65.00 | 71.41 | 70.81 | 65.63 | 63.22 | 58.52 | 65.07 | 90.41 | 90.33 | 88.32 |
| CWIP | 0.03 | 0.03 | 0.68 | 0.67 | 0.51 | 4.80 | 7.05 | 8.92 | 19.96 | 8.57 | 0.82 | 0.00 | 2.95 |
| Investments | 0.00 | 0.00 | 0.00 | 1.03 | 18.19 | 9.75 | 6.03 | 2.05 | 3.62 | 2.97 | 3.45 | 3.64 | 4.88 |
| Other Assets | 69.51 | 63.43 | 56.63 | 88.55 | 118.23 | 137.21 | 162.75 | 154.24 | 140.00 | 151.62 | 102.38 | 109.83 | 110.75 |
| Total Assets | 190.42 | 171.35 | 122.41 | 155.25 | 208.34 | 222.57 | 241.46 | 228.43 | 222.10 | 228.23 | 197.06 | 203.80 | 206.90 |
Below is a detailed analysis of the balance sheet data for JHS Svendgaard Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 85.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 85.60 Cr..
- For Reserves, as of Sep 2025, the value is 88.04 Cr.. The value appears strong and on an upward trend. It has increased from 87.12 Cr. (Mar 2025) to 88.04 Cr., marking an increase of 0.92 Cr..
- For Borrowings, as of Sep 2025, the value is 10.59 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 6.46 Cr. (Mar 2025) to 10.59 Cr., marking an increase of 4.13 Cr..
- For Other Liabilities, as of Sep 2025, the value is 22.67 Cr.. The value appears to be improving (decreasing). It has decreased from 24.62 Cr. (Mar 2025) to 22.67 Cr., marking a decrease of 1.95 Cr..
- For Total Liabilities, as of Sep 2025, the value is 206.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
- For Fixed Assets, as of Sep 2025, the value is 88.32 Cr.. The value appears to be declining and may need further review. It has decreased from 90.33 Cr. (Mar 2025) to 88.32 Cr., marking a decrease of 2.01 Cr..
- For CWIP, as of Sep 2025, the value is 2.95 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 2.95 Cr., marking an increase of 2.95 Cr..
- For Investments, as of Sep 2025, the value is 4.88 Cr.. The value appears strong and on an upward trend. It has increased from 3.64 Cr. (Mar 2025) to 4.88 Cr., marking an increase of 1.24 Cr..
- For Other Assets, as of Sep 2025, the value is 110.75 Cr.. The value appears strong and on an upward trend. It has increased from 109.83 Cr. (Mar 2025) to 110.75 Cr., marking an increase of 0.92 Cr..
- For Total Assets, as of Sep 2025, the value is 206.90 Cr.. The value appears strong and on an upward trend. It has increased from 203.80 Cr. (Mar 2025) to 206.90 Cr., marking an increase of 3.10 Cr..
Notably, the Reserves (88.04 Cr.) exceed the Borrowings (10.59 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -57.90 | -22.67 | 3.95 | 9.42 | 11.46 | -7.09 | -6.87 | -5.04 | -7.03 | -11.65 | -6.06 | -10.47 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 188 | 167 | 25 | 48 | 111 | 158 | 252 | 213 | 77 | 80 | 66 | 52 |
| Inventory Days | 122 | 94 | 53 | 95 | 65 | 60 | 30 | 97 | 114 | 128 | 176 | 153 |
| Days Payable | 95 | 106 | 67 | 123 | 153 | 134 | 177 | 128 | 130 | 197 | 197 | 141 |
| Cash Conversion Cycle | 215 | 156 | 12 | 19 | 23 | 85 | 105 | 182 | 61 | 11 | 46 | 63 |
| Working Capital Days | -708 | -39 | 58 | 56 | 122 | 173 | 198 | 272 | 217 | 41 | 51 | 48 |
| ROCE % | -10% | -12% | -3% | 5% | 8% | -0% | 4% | 1% | 1% | -2% | -2% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Diluted EPS (Rs.) | -2.37 | -0.52 | -2.34 | -0.63 | 0.20 |
| Cash EPS (Rs.) | -1.38 | 0.29 | -1.43 | 0.42 | 1.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.18 | 21.67 | 27.78 | 30.05 | 30.74 |
| Revenue From Operations / Share (Rs.) | 10.75 | 9.03 | 14.82 | 13.29 | 15.65 |
| PBDIT / Share (Rs.) | -0.13 | 0.43 | 0.81 | 1.32 | 1.47 |
| PBIT / Share (Rs.) | -1.06 | -0.37 | -0.33 | 0.23 | 0.34 |
| PBT / Share (Rs.) | -1.46 | -0.43 | -3.37 | 0.01 | 0.15 |
| Net Profit / Share (Rs.) | -2.31 | -0.51 | -2.58 | -0.66 | 0.20 |
| NP After MI And SOA / Share (Rs.) | -2.31 | -0.51 | -2.38 | -0.62 | 0.18 |
| PBDIT Margin (%) | -1.23 | 4.77 | 5.50 | 9.91 | 9.39 |
| PBIT Margin (%) | -9.87 | -4.19 | -2.25 | 1.73 | 2.19 |
| PBT Margin (%) | -13.59 | -4.84 | -22.70 | 0.11 | 0.96 |
| Net Profit Margin (%) | -21.46 | -5.73 | -17.43 | -4.97 | 1.33 |
| NP After MI And SOA Margin (%) | -21.46 | -5.73 | -16.07 | -4.69 | 1.18 |
| Return on Networth / Equity (%) | -11.43 | -2.38 | -8.96 | -2.17 | 0.63 |
| Return on Capital Employeed (%) | -5.14 | -1.70 | -1.09 | 0.73 | 1.07 |
| Return On Assets (%) | -9.81 | -2.05 | -6.54 | -1.82 | 0.52 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.46 | 0.32 | 0.41 | 0.36 | 0.42 |
| Current Ratio (X) | 2.18 | 1.87 | 2.36 | 4.18 | 5.23 |
| Quick Ratio (X) | 1.70 | 1.33 | 2.00 | 3.54 | 4.73 |
| Inventory Turnover Ratio (X) | 7.50 | 3.11 | 4.36 | 5.16 | 8.94 |
| Interest Coverage Ratio (X) | -2.01 | 7.34 | 5.09 | 6.13 | 7.63 |
| Interest Coverage Ratio (Post Tax) (X) | -28.88 | -7.82 | 2.78 | -2.08 | 2.08 |
| Enterprise Value (Cr.) | 81.22 | 121.69 | 70.51 | 136.74 | 117.07 |
| EV / Net Operating Revenue (X) | 0.88 | 1.72 | 0.73 | 1.59 | 1.16 |
| EV / EBITDA (X) | -71.68 | 36.03 | 13.31 | 15.99 | 12.37 |
| MarketCap / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| Price / BV (X) | 0.55 | 0.75 | 0.59 | 0.71 | 0.68 |
| Price / Net Operating Revenue (X) | 1.04 | 1.81 | 1.06 | 1.55 | 1.27 |
| EarningsYield | -0.20 | -0.03 | -0.15 | -0.03 | 0.01 |
After reviewing the key financial ratios for JHS Svendgaard Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Diluted EPS (Rs.), as of Mar 25, the value is -2.37. This value is below the healthy minimum of 5. It has decreased from -0.52 (Mar 24) to -2.37, marking a decrease of 1.85.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.38. This value is below the healthy minimum of 3. It has decreased from 0.29 (Mar 24) to -1.38, marking a decrease of 1.67.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.18. It has decreased from 21.67 (Mar 24) to 20.18, marking a decrease of 1.49.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 10.75. It has increased from 9.03 (Mar 24) to 10.75, marking an increase of 1.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.13. This value is below the healthy minimum of 2. It has decreased from 0.43 (Mar 24) to -0.13, marking a decrease of 0.56.
- For PBIT / Share (Rs.), as of Mar 25, the value is -1.06. This value is below the healthy minimum of 0. It has decreased from -0.37 (Mar 24) to -1.06, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.46. This value is below the healthy minimum of 0. It has decreased from -0.43 (Mar 24) to -1.46, marking a decrease of 1.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.31. This value is below the healthy minimum of 2. It has decreased from -0.51 (Mar 24) to -2.31, marking a decrease of 1.80.
- For PBDIT Margin (%), as of Mar 25, the value is -1.23. This value is below the healthy minimum of 10. It has decreased from 4.77 (Mar 24) to -1.23, marking a decrease of 6.00.
- For PBIT Margin (%), as of Mar 25, the value is -9.87. This value is below the healthy minimum of 10. It has decreased from -4.19 (Mar 24) to -9.87, marking a decrease of 5.68.
- For PBT Margin (%), as of Mar 25, the value is -13.59. This value is below the healthy minimum of 10. It has decreased from -4.84 (Mar 24) to -13.59, marking a decrease of 8.75.
- For Net Profit Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 5. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -21.46. This value is below the healthy minimum of 8. It has decreased from -5.73 (Mar 24) to -21.46, marking a decrease of 15.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is -11.43. This value is below the healthy minimum of 15. It has decreased from -2.38 (Mar 24) to -11.43, marking a decrease of 9.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.14. This value is below the healthy minimum of 10. It has decreased from -1.70 (Mar 24) to -5.14, marking a decrease of 3.44.
- For Return On Assets (%), as of Mar 25, the value is -9.81. This value is below the healthy minimum of 5. It has decreased from -2.05 (Mar 24) to -9.81, marking a decrease of 7.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has increased from 0.32 (Mar 24) to 0.46, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 2.18, marking an increase of 0.31.
- For Quick Ratio (X), as of Mar 25, the value is 1.70. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.70, marking an increase of 0.37.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.50. This value is within the healthy range. It has increased from 3.11 (Mar 24) to 7.50, marking an increase of 4.39.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.01. This value is below the healthy minimum of 3. It has decreased from 7.34 (Mar 24) to -2.01, marking a decrease of 9.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -28.88. This value is below the healthy minimum of 3. It has decreased from -7.82 (Mar 24) to -28.88, marking a decrease of 21.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 81.22. It has decreased from 121.69 (Mar 24) to 81.22, marking a decrease of 40.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 1.72 (Mar 24) to 0.88, marking a decrease of 0.84.
- For EV / EBITDA (X), as of Mar 25, the value is -71.68. This value is below the healthy minimum of 5. It has decreased from 36.03 (Mar 24) to -71.68, marking a decrease of 107.71.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For Price / BV (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.55, marking a decrease of 0.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.81 (Mar 24) to 1.04, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from -0.03 (Mar 24) to -0.20, marking a decrease of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in JHS Svendgaard Laboratories Ltd:
- Net Profit Margin: -21.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.14% (Industry Average ROCE: 29.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -11.43% (Industry Average ROE: 23.91%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -28.88
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 56.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -21.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Personal Care | Trilokpur Road, Kheri (Kala Amb), Sirmour Dist. Himachal Pradesh 173030 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajagopal Chakravarthi Venkateish | Chairman & Ind.Director |
| Mr. Nikhil Nanda | Managing & Executive Director |
| Mr. Vinay Mittal | Non Executive Director |
| Mr. Kapil Minocha | Independent Director |
| Mrs. Upma Chawdhry | Independent Woman Director |
FAQ
What is the intrinsic value of JHS Svendgaard Laboratories Ltd?
JHS Svendgaard Laboratories Ltd's intrinsic value (as of 29 January 2026) is ₹25.46 which is 152.08% higher the current market price of ₹10.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹86.6 Cr. market cap, FY2025-2026 high/low of ₹20.7/8.66, reserves of ₹88.04 Cr, and liabilities of ₹206.90 Cr.
What is the Market Cap of JHS Svendgaard Laboratories Ltd?
The Market Cap of JHS Svendgaard Laboratories Ltd is 86.6 Cr..
What is the current Stock Price of JHS Svendgaard Laboratories Ltd as on 29 January 2026?
The current stock price of JHS Svendgaard Laboratories Ltd as on 29 January 2026 is ₹10.1.
What is the High / Low of JHS Svendgaard Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of JHS Svendgaard Laboratories Ltd stocks is ₹20.7/8.66.
What is the Stock P/E of JHS Svendgaard Laboratories Ltd?
The Stock P/E of JHS Svendgaard Laboratories Ltd is .
What is the Book Value of JHS Svendgaard Laboratories Ltd?
The Book Value of JHS Svendgaard Laboratories Ltd is 20.3.
What is the Dividend Yield of JHS Svendgaard Laboratories Ltd?
The Dividend Yield of JHS Svendgaard Laboratories Ltd is 0.00 %.
What is the ROCE of JHS Svendgaard Laboratories Ltd?
The ROCE of JHS Svendgaard Laboratories Ltd is 5.19 %.
What is the ROE of JHS Svendgaard Laboratories Ltd?
The ROE of JHS Svendgaard Laboratories Ltd is 10.8 %.
What is the Face Value of JHS Svendgaard Laboratories Ltd?
The Face Value of JHS Svendgaard Laboratories Ltd is 10.0.